Insider sales at this magnitude relative to market cap are routine. Duato's 10b5-1 plan likely governs these sales post-vesting. No actionable signal, monitor next 8-K or earnings for any material change in fundamentals.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $261.81entry
- T+1 · 3mo ago −0.77%α −0.45% · $259.80
- T+5 · 3mo ago +0.21%α +0.26% · $262.37
- T+20 · 2mo ago +2.79%α +3.71% · $269.12
- T+60 · 14d ago +1.67%α +4.08% · $266.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
JNJ CEO Joaquin Duato and EVP/Chief Legal Officer Elizabeth Forminard executed ~$16.6M in open-market sales over two days. The CEO's $12.5M sale and CLO's combined $4.1M sale are modest relative to JNJ's $619B market cap (~0.0027%), making this a routine portfolio diversification event with negligible signal in a mega-cap pharmaceutical stock.
Key Financial Metrics
Key Facts
- CEO Joaquin Duato sold 48,480 shares for ~$12.5M on 2026-08-05
- EVP/Chief Legal Officer Elizabeth Forminard sold 15,918 shares for ~$4.1M on 2026-08-06
- Forminard's sales followed the exercise of 9,344 derivative shares at $131.94 (cash exercise) and 9,344 shares at $0 (non-cash)
- Total open-market sales of ~$16.6M represent ~0.0027% of JNJ's $619B market cap
Financial Impact
$16.6M in insider sales, immaterial relative to $619B market cap
Risk Factors
- Large insider sales from senior executives could be misread by retail traders as a negative signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-JNJ-1786140079824 |
Track record
21 reports on JNJ
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Viewing Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers